Please use this identifier to cite or link to this item: https://cris.library.msu.ac.zw//handle/11408/5653
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSharon R Mutengaen_US
dc.contributor.authorBonolo B Phiniusen_US
dc.contributor.authorMotswedi Andersonen_US
dc.contributor.authorIrene Gobeen_US
dc.contributor.authorMargaret Mokomaneen_US
dc.contributor.authorWonderful T Chogaen_US
dc.contributor.authorGorata Mpebeen_US
dc.contributor.authorMolly Pretorius-Holmeen_US
dc.contributor.authorRosemary Musondaen_US
dc.contributor.authorTendani Gaolatheen_US
dc.contributor.authorMompati Mmalaneen_US
dc.contributor.authorRoger Shapiroen_US
dc.contributor.authorJoseph Makhemaen_US
dc.contributor.authorShahin Lockmanen_US
dc.contributor.authorVlad Novitskyen_US
dc.contributor.authorMax Essexen_US
dc.contributor.authorSikhulile Moyoen_US
dc.contributor.authorSimani Gaseitsiween_US
dc.date.accessioned2023-05-22T07:22:03Z-
dc.date.available2023-05-22T07:22:03Z-
dc.date.issued2023-01-06-
dc.identifier.urihttps://cris.library.msu.ac.zw//handle/11408/5653-
dc.description.abstractBackground,We aimed to determine the prevalence of hepatitis B virus (HBV) infection among people with human immunodeficiency virus (PWH) in rural and periurban communities in Botswana.Methods.PWH from a previous population-based study, the Botswana Prevention Combination Project, which enrolled adults in 30 communities across Botswana (2013–2018), were screened for HBV surface antigen (HBsAg) and HBV core antibody (anti-HBc). HBsAg-positive (HBsAg+) samples were further screened for HBV core immunoglobulin M antibodies (anti-HBc immunoglobulin M [IgM]) and HBV e antigen (HBeAg). We quantified HBV viral load on participants who tested positive (n = 148) and negative for HBsAg (n = 381). Results.Of 3304 participants tested, 271 (8% [95% confidence interval {CI}, 7%–9%]) were HBsAg+ while 1788 (56% [95% CI, 54%–57%]) of 3218 PWH whom we tested had positive anti-HBc. Approximately 88% of HBsAg+ participants were on antiretroviral therapy (ART), 40% and 56% of whom were receiving lamivudine- and tenofovir-containing ART, respectively. Male sex (relative risk ratio [RRR], 1.8 [95% CI, 1.2–2.7]) and the northern geographic region (RRR, 2.5 [95% CI, 1.4–4.7]) were independent predictors of HBV infection (HBsAg+). Of 381 persons with negative HBsAg who were tested for occult HBV, 126 (33% [95% CI, 29%–38%]) had positive HBV DNA. Eleven participants were highly viremic with high HBV viral load while on a lamivudine- or tenofovir-containing regimen. Ten (91%) of these participants also had positive HBeAg serology, while 4 (36%) had positive anti-HBc IgM serology. Conclusions.The prevalence of HBV was high among PWH in Botswana while on ART regimens with activity against HBV.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofOpen Forum Infectious Diseasesen_US
dc.subjectAfrica,en_US
dc.subjectBotswanaen_US
dc.subjecthepatitis B virusen_US
dc.subjecthuman immunodeficiency virusen_US
dc.subjectoccult HBVen_US
dc.titleHigh Prevalence of Hepatitis B Virus Infection Among People With HIV in Rural and Periurban Communities in Botswanaen_US
dc.typeresearch articleen_US
dc.identifier.doihttps://doi.org/10.1093/ofid/ofac707-
dc.contributor.affiliationDepartment of Applied Biological Sciences and Biotechnology, Faculty of Science and Technology, Midlands State University, Gweru, Zimbabwe.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationSchool of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationSchool of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswanaen_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Biological Sciences, Faculty of Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.relation.issn2328-8957en_US
dc.description.volume10en_US
dc.description.issue1en_US
dc.description.startpage1en_US
dc.description.endpage15en_US
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.openairetyperesearch article-
item.languageiso639-1en-
Appears in Collections:Research Papers
Show simple item record

Page view(s)

36
checked on May 15, 2024

Download(s)

2
checked on May 15, 2024

Google ScholarTM

Check

Altmetric


Items in MSUIR are protected by copyright, with all rights reserved, unless otherwise indicated.